Your browser doesn't support javascript.
loading
Postoperative radiotherapy versus surgery alone in pN1 oral cavity cancer patients: A meta-analysis.
Tsai, Tsung-You; Chiang, Pin-Chun; Yap, Wing-Keen; Huang, Yenlin; See, Anna; Hung, Shao-Yu; Lu, Chuieng-Yi; Lin, Chien-Yu; Chang, Tung-Chieh Joseph; Kao, Huang-Kai; Chang, Kai-Ping.
Afiliação
  • Tsai TY; Department of Otolaryngology-Head and Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Chiang PC; Department of Otolaryngology-Head and Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Yap WK; College of Medicine Chang Gung University Taoyuan Taiwan.
  • Huang Y; Proton and Radiation Therapy Center, Chang Gung Memorial Hospital-Linkou Medical Center, Department of Radiation Oncology Chang Gung University Taoyuan Taiwan.
  • See A; Department of Anatomic Pathology Chang Gung Memorial Hospital at Linkou Branch Taoyuan Taiwan.
  • Hung SY; Institute of Stem Cell and Translation Cancer Research Chang Gung Memorial Hospital at Linkou Branch Taoyuan Taiwan.
  • Lu CY; School of Medicine National Tsing-Hua University Hsinchu Taiwan.
  • Lin CY; Department of Otolaryngology-Head and Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan.
  • Chang TJ; Department of Otorhinolaryngology-Head and Neck Surgery Singapore General Hospital Singapore.
  • Kao HK; Department of Plastic and Reconstructive Surgery Chang Gung Memorial Hospital at Linkou Branch Taoyuan Taiwan.
  • Chang KP; Department of Plastic and Reconstructive Surgery Chang Gung Memorial Hospital at Linkou Branch Taoyuan Taiwan.
Laryngoscope Investig Otolaryngol ; 9(3): e1260, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38751691
ABSTRACT

Objectives:

The aim of this meta-analysis is to evaluate the potential benefits of postoperative radiotherapy (PORT) in patients with pN1 oral cavity squamous cell carcinoma.

Methods:

A literature search through major databases was conducted until January 2023. The adjusted hazard ratio (aHR) or risk ratio (RR) with 95% confidence intervals (CIs) of different survival outcomes were extracted and pooled.

Results:

Ten studies published between 2005 and 2022, with a pooled patient population of 2888, were included in this meta-analysis. Due to differences in study design and reported outcomes, the studies were categorized into distinct groups. In pN1 patients without extranodal extension (ENE), PORT was associated with a significant improvement in overall survival (OS) (aHR 0.76, 95% CI 0.61-0.94). In pN1 patients without ENE and positive margins, PORT improved OS (aHR 0.71, 95% CI 0.56-0.89) and was associated with a lower regional recurrence rate (RR 0.35, 95% CI 0.15-0.83). However, in pN1 patients without ENE, positive margins, perineural invasion, and lymphovascular invasion, there were no significant differences observed between the PORT and observation groups in either 5-year OS (RR 0.48, 95% CI 0.07-3.41) or 5-year disease-free survival (RR 0.37, 95% CI 0.07-2.06).

Conclusions:

The current study demonstrated that PORT has the potential to improve OS in pN1 disease. However, the decision of whether to administer PORT still hinges on diverse clinical scenarios, and additional research is necessary to furnish a more conclusive resolution. Level of Evidence 2.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article